News & Updates
Showing Multidisciplinary articles
Showing

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer
The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.

Young-onset diabetes programme provides DNA testing and precision preventive intervention to those at risk
A programme targeting 9,000 adults 18–44 years of age will identify individuals with high 10-year risk of diabetes through DNA testing and provide precision preventive intervention.

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.





